ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1617941
This article is part of the Research TopicUsing Oncolytic Viruses in Cancer Immunity and Immunotherapy: Hepatocellular Carcinoma, Gastric Cancer, and Colorectal CancerView all articles
Mechanism of Action of Over-Expressing NY-ESO-1 in Vesicular Stomatitis Virus and its Combination Therapy with NY-ESO-1 TCR-T
Provisionally accepted
- Joint Biosciences (SH) Ltd, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
： Vesicular Stomatitis Virus ( VSV ) has several advantages, including a short replication cycle, broad tissue tropism, low natural infection rate in humans, and a small genome that is easy to manipulate. In this study, we constructed an attenuated OVV-01 carrying the tumor-associated antigen (TAA) NY-ESO-1 gene. In vitro experiments showed that OVV-01 strongly inhibits the growth of various tumor cells. The NY-ESO-1 protein overexpressed in tumor cells can be presented on the cell surface and recognized by effector T cells carrying the corresponding TCR, leading to further killing of tumor cells. Studies in mouse models revealed that OVV-01 has the ability to selectively replicate in tumor tissues. Compared to OVV-00 (a control virus without exogenous genes), OVV-01 more effectively stimulated hCD8+ and hCD4+ T cells, as well as the NY-ESO-1 specific TCR-T cells, resulting in more efficient control of tumor growth. Both in vitro and in vivo experiments also demonstrated that the combined application of OVV-01 and TCR-T cells significantly enhances the tumor growth inhibition mediated by TCR-T cells.
Keywords: Vesicular Stomatitis Virus(VSV), NY-ESO-1, tumor, TCR-T cell, Combination (Combined) Therapy
Received: 25 Apr 2025; Accepted: 25 Jul 2025.
Copyright: © 2025 Zhou, Tian, Ma, Mao, Wang, Cheng, Ma and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guoqing Zhou, Joint Biosciences (SH) Ltd, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.